Power to all sales reps
The pharmaceutical industry needs to jettison its historic ‘quantity over quality’ attitude to sales and marketing. With healthcare professionals harder to access by the...
New Regulations for Recruiters
The Implications for both Clients and Candidates Do you use Recruiters to help you fill vacancies for permanent or temporary staff? Or are you...
Movements in the NHS: Hospital to Alternate Site
By Gordon Blackwell, The National Health Intelligence Service Whenever possible, patient care is being moved away from hospitals into the community, so that, within...
Pharma-logically Speaking! (Part 2)
I have come to realise that many ‘discussions’ around a sales call come down to ‘beliefs’. And to ‘effect change in one’s beliefs’ relies...
The New PPRS Agreement
THE NEW PPRS scheme (Prescription Price Regulatory Scheme) comes into force from the 1st January 2005 with the aim of reducing the cost of...
Thank You – This is all About You: A people Orientated Sector
Culture . . . Does it make a difference? Is the culture of your company unique? Are you amongst the best and are you...
Clinical Trial Transparency
While the issue of clinical trial transparency has long been an area of controversy, the matter has certainly hit the headlines in recent months....
Pharma-logically Speaking!
I have come to realise that many ‘discussions’ around a sales call come down to ‘beliefs’. And to ‘effect change in one’s beliefs’ relies...
Sales, Sales and More Sales Please – An Accountable Sector
WHY DID YOU join the industry and become a sales person? Was it to sell through managing your own territory and influencing prescribers, or...
High cost of new Cancer drugs too high for some?
The world’s aging population is expected to facilitate a 50% increase in the global incidence of cancer over the next two decades, with the...
Latest articles
Antibody designed to recognise Alzheimer’s disease pathogens
Researchers have found a way to design an antibody that can recognise Alzheimer's disease pathogens. It can identify the toxic particles that destroy healthy...
LifeArc backs trials to re-purpose drugs for COVID-19 therapies
Medical research charity, LifeArc is providing £10m for clinical trials to find effective COVID-19 therapies. All 15 projects – involving nearly 30 different organisations...
New guidelines for COVID-19 vaccine development: ethical approach to infecting volunteers
Allowing consenting volunteers to be deliberately infected with COVID-19 for the purposes of COVID-19 vaccine development could be done ethically and potentially speed up...
Popular articles
LifeArc backs trials to re-purpose drugs for COVID-19 therapies
Medical research charity, LifeArc is providing £10m for clinical trials to find effective COVID-19 therapies. All 15 projects – involving nearly 30 different organisations...
Study shows anti-parasitic drug ivermectin kills coronavirus within 48 hours
A collaborative study led by the Monash Biomedicine Discovery Institute (BDI) with the Peter Doherty Institute of Infection and Immunity (Doherty Institute), a joint...
New treatment option for extensive-stage small-cell lung cancer approved
A new treatment option for patients with extensive-stage small-cell lung cancer has been approved by the National Institute for Health and Care Excellence (NICE). In...
Antibody designed to recognise Alzheimer’s disease pathogens
Researchers have found a way to design an antibody that can recognise Alzheimer's disease pathogens. It can identify the toxic particles that destroy healthy...
Novartis’ Kisqali® shows overall survival benefit in advanced breast cancer
Novartis has announced a new exploratory subgroup analysis of the Phase III MONALEESA-3 and MONALEESA-7 trials, reinforcing the overall survival (OS) benefit of Kisqali®...